Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced a strategic collaboration with TARA Mind, in partnership with Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The initiative aims to expand mental health awareness within the veteran community while advancing the development of HLP003, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA).
The partnership leverages the networks of TARA Mind and VETS to enhance veteran engagement, aligning with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness. Helus Pharma is developing HLP003 as a proprietary novel serotonergic agonist (NSA) designed to activate serotonin pathways believed to promote neuroplasticity, offering durable improvements in mental health. The company also has HLP004 in Phase 2 for generalized anxiety disorder and an extensive research portfolio of investigational NSAs.
“This collaboration with TARA Mind and VETS represents a significant step in our mission to help minds heal,” said a Helus Pharma spokesperson. “By engaging directly with the veteran community, we aim to raise awareness about the potential of HLP003 and ensure that those who have served our country have access to innovative treatment options.” TARA Mind, a organization focused on mental health support for veterans, will facilitate outreach and education efforts to connect eligible participants with the Phase 3 trial.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical-stage pharmaceutical company committed to addressing unmet mental health needs. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
This partnership underscores the importance of targeted recruitment strategies in clinical research, particularly for conditions like major depressive disorder that disproportionately affect veterans. By combining Helus Pharma’s scientific expertise with TARA Mind’s community reach, the program aims to accelerate the development of HLP003 and potentially provide a new treatment option for those suffering from depression.
